WO1989000043A1 - Ophthalmic agent and related compositions and method for treatment of the cornea - Google Patents
Ophthalmic agent and related compositions and method for treatment of the cornea Download PDFInfo
- Publication number
- WO1989000043A1 WO1989000043A1 PCT/EP1988/000606 EP8800606W WO8900043A1 WO 1989000043 A1 WO1989000043 A1 WO 1989000043A1 EP 8800606 W EP8800606 W EP 8800606W WO 8900043 A1 WO8900043 A1 WO 8900043A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- connective tissue
- tissue matrix
- sterile
- extracellular connective
- matrix extract
- Prior art date
Links
- 210000004087 cornea Anatomy 0.000 title claims abstract description 51
- 239000003732 agents acting on the eye Substances 0.000 title claims abstract description 26
- 229940125702 ophthalmic agent Drugs 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims description 76
- 238000000034 method Methods 0.000 title claims description 58
- 238000011282 treatment Methods 0.000 title description 19
- 239000011159 matrix material Substances 0.000 claims abstract description 69
- 210000002808 connective tissue Anatomy 0.000 claims abstract description 63
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- 229920001436 collagen Polymers 0.000 claims description 62
- 108010035532 Collagen Proteins 0.000 claims description 61
- 102000008186 Collagen Human genes 0.000 claims description 61
- 239000000284 extract Substances 0.000 claims description 50
- 210000001519 tissue Anatomy 0.000 claims description 42
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 26
- 102000016611 Proteoglycans Human genes 0.000 claims description 22
- 108010067787 Proteoglycans Proteins 0.000 claims description 22
- 102000003886 Glycoproteins Human genes 0.000 claims description 16
- 108090000288 Glycoproteins Proteins 0.000 claims description 16
- 238000001727 in vivo Methods 0.000 claims description 11
- 210000000845 cartilage Anatomy 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 7
- 210000004204 blood vessel Anatomy 0.000 claims description 7
- 230000035876 healing Effects 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 210000003954 umbilical cord Anatomy 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 210000004291 uterus Anatomy 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 210000002219 extraembryonic membrane Anatomy 0.000 claims 5
- 210000005059 placental tissue Anatomy 0.000 claims 5
- 239000006071 cream Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 abstract description 5
- 238000007634 remodeling Methods 0.000 abstract description 5
- 230000005855 radiation Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 32
- 210000001508 eye Anatomy 0.000 description 24
- 210000002744 extracellular matrix Anatomy 0.000 description 23
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 22
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 22
- 239000000126 substance Substances 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 239000002674 ointment Substances 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 12
- 239000000835 fiber Substances 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000008439 repair process Effects 0.000 description 11
- 239000002537 cosmetic Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 102000016359 Fibronectins Human genes 0.000 description 8
- 108010067306 Fibronectins Proteins 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 230000008733 trauma Effects 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000000795 conjunctiva Anatomy 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000028006 Corneal injury Diseases 0.000 description 5
- 102000016942 Elastin Human genes 0.000 description 5
- 108010014258 Elastin Proteins 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 210000003560 epithelium corneal Anatomy 0.000 description 5
- 235000019271 petrolatum Nutrition 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 210000004045 bowman membrane Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical group 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 150000002016 disaccharides Chemical group 0.000 description 4
- 229920002549 elastin Polymers 0.000 description 4
- 210000001723 extracellular space Anatomy 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000002262 irrigation Effects 0.000 description 4
- 238000003973 irrigation Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 210000003786 sclera Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010001478 Bacitracin Proteins 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 3
- 206010010741 Conjunctivitis Diseases 0.000 description 3
- 206010023644 Lacrimation increased Diseases 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- 206010034960 Photophobia Diseases 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960003071 bacitracin Drugs 0.000 description 3
- 229930184125 bacitracin Natural products 0.000 description 3
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004317 lacrimation Effects 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000009043 Chemical Burns Diseases 0.000 description 2
- 206010010984 Corneal abrasion Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010017012 Foreign body in eye Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022941 Iridocyclitis Diseases 0.000 description 2
- 241000446313 Lamella Species 0.000 description 2
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 2
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 201000004612 anterior uveitis Diseases 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 208000010217 blepharitis Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 230000003500 cycloplegic effect Effects 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000299 nuclear matrix Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 206010044325 trachoma Diseases 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- BFUUJUGQJUTPAF-UHFFFAOYSA-N 2-(3-amino-4-propoxybenzoyl)oxyethyl-diethylazanium;chloride Chemical compound [Cl-].CCCOC1=CC=C(C(=O)OCC[NH+](CC)CC)C=C1N BFUUJUGQJUTPAF-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000634805 Alacia Species 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 108700016947 Bos taurus structural-GP Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000032812 Chemical iritis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 208000018465 Conjunctival injury Diseases 0.000 description 1
- 206010010996 Corneal degeneration Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010011844 Dacryocystitis Diseases 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 208000020564 Eye injury Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 206010023335 Keratitis interstitial Diseases 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010067193 Naevus flammeus Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 108010077465 Tropocollagen Proteins 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000004781 bullous keratopathy Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 108010085318 carboxymethylcellulase Proteins 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940108956 chloramphenicol 5 mg/ml Drugs 0.000 description 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- PIQVDUKEQYOJNR-VZXSFKIWSA-N cocaine hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@H]2CC[C@@H]([NH+]2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 PIQVDUKEQYOJNR-VZXSFKIWSA-N 0.000 description 1
- 229960003771 cocaine hydrochloride Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 201000006901 congenital syphilis Diseases 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000000871 endothelium corneal Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 229940048319 erythromycin 50 mg/ml Drugs 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 201000006904 interstitial keratitis Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229960001371 proparacaine hydrochloride Drugs 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229940110762 sulfacetamide ophthalmic solution Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940108969 tobramycin 3 mg/ml Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940071288 vancomycin 50 mg/ml Drugs 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
Definitions
- This invention relates to ophthalmic agents and compositions for the repair and remodeling of damaged corneal tissue. This invention also relates to a method for treating damaged corneal tissue with these agents and compositions.
- Damage to the cornea can be attributed to a variety of factors. Some of these factors are ultraviolet radiation, aging, thermal and chemical burns (acid or alkali) and physical trauma. It is important from a therapeutic point of view to conserve an intact epithelial-matrix junction membrane and to assist in the rapid repair of damaged corneal tissue. Since a damaged cornea results in limited visual functionality.
- the underlying problem addressed by the present invention has been the inability, to date, to provide a composition or treatment which would enable the repair damaged corneal tissue.
- This invention therefore, relates to ophthalmic agents, compositions and methods for their use which, utilizing appropriate therapy, are effective in repairing and remodeling damaged corneal tissue. More specifically, the ophthalmic agents utilized in this invention provide essential components of the extracellular connective tissue matrix in their natural or native, unaltered structural form, which provide a physiological matrix required to repair damaged corneal tissue. The result of treatment with these ophthalmic agents is a cornea wherein the normal physiological visual functioning has been restored.
- the eye apart from its physical shape, has many of the structural features of the camera.
- the eyelids compromise the shutter.
- the iris is a diaphragm which contacts and dilates automatically in relation to the amount of light available.
- the eye has a lens composed of altered transparent epithelial cells but which is more elastic than the glass lens of a camera.
- the lens of the eye as opposed to a camera, is suspended in such a way that muscle action can alter its shape and so change its focal length. As a consequence, the eye need not be shortened or elongated when objects at different distances are successively brought into focus as is necessary in a camera with a rigid lens.
- the a camera has its counterpart in the eye in strong connective tissue membrane, the sclera.
- the counterpart in the eye of the light-sensitive film used in a camera is a membrane of living cells of nervous origin, the retina, which lines not only the back but the sides of the eye as well. Then, finally, just as black is used to blacken all the interior surfaces of a camera that might leak or reflect light, black pigment is distributed generously between the retina and the sclera and in other sites where it would be useful.
- the lens of the eye is not placed at its very front.
- the eye has its external aperture covered with a "glass window to keep out the dust", and its lens inside, a short distance behind the glass window.
- the transparent window in the central part of the front of the eye is of a curved form and is called the cornea. This is composed chiefly of a tough but:
- the cornea plays a larger role than the lens in - focusing the image upon the retina because light retina because light rays are bent more in passing from air into and out of the lens.
- the surface of the cornea is curved so that light rays coming from a single point source hit the cornea at different angles and are bent different amounts. But all in such a way that they are directed to a point after emerging from the lens.
- the shape of the cornea and lens and the length of the eyeball determine the point where light rays reconverge.
- the cornea performs the greater part quantitatively of focusing the visual image on the retina, all adjustments of distance are made by changing the shap of the lens. Such changes are called accommodation.
- the shape of the lens is controlled by a muscle which flattens the lens when distant objects are to be focused upon the retina and allows it to assume a more spherical shape to provide additional bending of the light rays when rear objects are viewed.
- the cornea is the anterior part of the supporting layer of the eye. It is a transparent, nonvascular membrane. It has a shorter radius of curvature than the remainder of the wall of the eye. Since it is exposed, it is subject to cuts, abrasions and other kinds of trauma. It is important in treating
- ⁇ injuries of the cornea to know its thickness It is about 0.5 mm. thick at its central part and somewhat thicker at its periphery.
- the cornea consists chiefly of a special kind of dense connective tissue, containing both cells and intercellular substance, called the substant a laminate.
- cornea This bordered anteriorly and posteriorly by a membrane of homogeneous intercellular substance.
- cornea is covered with stratified squamous nonkeratinizing epithelium and posteriorly it is lined by a single layer of endothelial cells.
- the epithelium covering the cornea is several layers in thickness and is replete with nerve endings tha ⁇ are chiefly of the pain type. Their stimulation results reflexly in the blinking of the eyelids and in the flow of tears (mucus from the conjunctival glands also helps keep the corneal surface wet) ; if the nerve pathways concerned in the reflexes described above are destroyed, the corneal surface, on not being frequently wiped by the wet lids, becomes dry and then ulcerated. There are no papillae projecting into the epithelium of the cornea. Furthermore, since the connective tissue beneath it has no capillaries, the epithelium of the cornea is a comparatively long way from source of nutrition. The diffusion phenomenon on which its cells depend must be very efficient, for corneal epithelium, on being injured, regenerates rapidly. Carbon dioxide is eliminated through the corneal epithelium.
- Bowman's membrane The membrane of intercelluar substance on which the basal cells of the corneal epithelium rests is called Bowman's membrane. This consists of a trans ⁇ arent
- SUBSTITUTE SHEET homogeneous material It is generally regarded as a condensation of the intercellular substance of the substantia basement. It contains some collagen and is regarded as an important protective layer, being resistant to trauma and bacterial invasion. Once destroyed, it does not regenerate. Bowman's membrane does not extend from the cornea into the sclera. The site at which cornea undergoes a transition into sclera and consequently, where Bowman's membrane ends is called the limbus.
- the substantia basement comprises about 90 percent of the thickness of the cornea. It contains flattened connective tissue cells that are disposed between parallel bundles of collagenic fibers called lamellae. While most of the fibers in the lamella are disposed parallel with surface, those of one lamella run at an angle to those of the next. The fibers of some lamellae join with those of adjacent lamellae to bind the substantia limbal together.
- the collagen fibrils and fibers are embedded in sulfated mucopolysaccharide containing proteoglycans and glycoproteins. It is assumed that the binding together of collagen fibrils in the substantia intestinal by the substance as well as their regular arrangement is responsible for the unique transparency of this membrane.
- Descement's membrane Deep to the substantia intestinal is Descement's membrane. This is composed of a special kind of material that appears to be homogeneous and seems to be chiefly an special form of collagen. Applied to the inner side of Descement's membrane is a single layer of endothelial cells; this laver is called Descement's endotheliu .
- the patient's vision, the range of extraocular motion, the location of lid and conjunctival lacerations and of foreign bodies, and the clarity of the ocular media should be carefully determined.
- the treatment typically is adequate light, good anesthesia, and proper instruments are essential to ensure minimal trauma when removing embedded foreign bodies. Fluorescein staining renders foreign bodies and abrasions more apparent.
- An anesthetic is instilled onto the conjunctiva. Both lids are everted and the entire conjunctiva and cornea inspected with a binocular lens (loupe) . Conjunctival foreign bodies are lifted out with a moist sterile cotton applicator. A corneal foreign body that cannot be dislodged by irrigation may be lifted out carefully on the point of a sterile spud or hypodermic needle, under loupe magnification.
- an antibiotic ointment e.g., erythromycin 0.5% or bacitracin 500 u./gm
- treatment is that for any corneal abrasion is usually dilating the pupil with a short-acting cycloplegic, instilling an antibiotic, usually erythromycin or bacitracin; and applying a patch firmly enough to keep the eye closed
- pain may require codeine 30 to 60 mg orally or meperidine
- UV rays e.g., from welding arcs, sun
- SUBSTITUTE SHEET lamps SUBSTITUTE SHEET lamps. Symptoms include photophobia, pain, lacrimation, conjunctival injection, and diminution of vision. An enlarged preauricular node may be present in viral cases. Lesions due to ultraviolet ray exposure do not appear until several hours after the exposure; they last 24 to 43 h. while those secondary to viral or bacterial agents may last for months. Healing is spontaneous and residual vision impairment is rare, regardless of etiology. Typically topical antimicrobial therapy is given promptly, particularly if a causative organism can be cultured and identified. A systemic analgesic may be needed for control of pain.
- corneal. ulcers a local necrosis of corneal tissue is due to invasion by microorganisms.
- a pneumococcal, streptococcal, or staphylococcal infection following trauma or complicating a corneal foreign body is the usual primary cause.
- Corneal ulcers also occur as complications of herpes simplex keratitis, chronic blepharitis, conjunctivitis (especially bacterial) , trachoma, dacryocystitis, gonorrhea, and acute infectious diseases. Pain, photophobia, blepharospasm, and lacrimation are usually present, but may be minimal.
- Ulceration without extensive infiltration may occur in herpes simplex. Fungal ulcerations are densely infiltrated and show occasions discrete islands of infiltrate (satellite lesions) at the periphery. The deeper the ulcer, the more severe the symptoms and complications. Ulcers deep enough to involve Bowman's membrane and the substance of the cornea heal with fibrous tissue replacement, causing opaque scarring of the cornea and decreased vision. Phlyctenular
- Keratoconjunctivitis is a form of conjunctivitis, usually- occurring in children, characterized by discrete nodular
- SHEET _ areas of inflammation and resulting from the atopic reaction of hypersensitive conjunctiva or cornea to an unknown allergen. Proteins of staphylococcal, tuberculous, or other bacterial origin have been implicated. The disease is rare in the USA.
- Interstitial keratitis is a form of a chronic nonulcerative infiltration of the deep layers of the cornea, with uveal inflammation. It is rare in the USA. Most cases occur in children as late complication of congenital syphilis. Ultimately, both eyes may be involved. Rarely, acquired syphilis or tuberculosis may cause a unilateral form in adults. Photophobia, pain, lacrimation, and gradual loss of vision are common. The lesion begins in the deep corneal layers; soon the entire cornea develops a ground-glass appearance, obscuring the iris. New blood vessels grow in from the li bus and produce orange-red areas ("salmon patches"). Iritis, iridocyclitis, and choroiditis are common.
- Kerato alacia is. a condition associated with vitamin A deficiency and protein-calorie malnutrition, characterized by a hazy, dry cornea that becomes denuded. Corneal ulceration with secondary infection is common. The lacrimal glands and conjunctiva are also affected. Lack of tears cause extreme dryness of the eyes, and foamy Bitot's spots ' appear on the bulbar conjunctiva. Nigh- blindness may be associated. Antibiotic ointments or sulfonamides (e.g., sulfacetamide ophthalmic solution 30% or ointment 10%) are required if secondary infection exists.
- Keratoconus is a slowly progressive ectasia of the cornea , usually bilateral , beginning between ages 10 and 20 .
- the cone shaoe that the cornea assumes causes
- Bullous keratopathy is a condition caused by excessive fluid accumulation in the cornea, most frequently the result of aging and failure of the posterior corneal endothelium. It is seen occasionally after intraocular operations (e.g., for cataract), where the mechanical stresses further interfere with the process of corneal detumescence.
- the vertebrate extracellular matrix was thought to serve mainly as a relatively inert scaffolding that stabilized the physical structure of tissues. But now it is clear that the matrix plays a far
- SUBSTITUTE SHEET more active and complex role in regulating the behavior of the cells that contact it - influencing their development, migration, proliferation, shape, and metabolic functions.
- the macromolecules that constitute the extracellular matrix are secreted by local cells, especially fibroblasts, which are widely distributed in the matrix.
- Two of the main classes of extracellular macromolecules that make up the matrix are (1) the collagens and (2) the polysaccharide glycosaminoglycans, which are usually covalently linked to protein to form proteoglycans.
- the gly ⁇ osaminoglycan and proteoglycan molecules form a highly hydrated, gel-like "ground substance" in which collagen fibers are embedded. While the long collagen fibers strengthen and help to organize the matrix, the aqueous phase of the polysaccharide gel permits the diffusion of nutrients, metabolites, and hormones between the blood and the tissue cells.
- fibers 'of the rubberlike protein elastin are also present and impart resilience to the matrix.
- two high molecular weight glycoproteins are among the major components of extracellular matrices: fibronectin, which is widely distributed in connective tissues, and laminin, which has so far been found only in basal laminae.
- connective tissue is often used to describe the extracellular matrix plus the cells found in it, such as fibroblasts, macrophages, and mast cells.
- the amount of connective tissue in organs varies greatly: the cornea, skin and bone are composed mainly of connective tissue, whereas the brain and spinal cord contain very little.
- SUBSTITUTE SHEET organized within the extracellular matrix vary enormously, giving rise to a diversity of forms, each highly adapted to the functional requirements of the particular tissue.
- the matrix can become calcified to form the rock- hard structures of bone or teeth, it may take on the ropelike organization of the collagen fibers in tendons, which gives them their enormous tensile strength, or it can form a clear window-like structure in the cornea.
- the collagens are a family of highly characteristic fibrous proteins found in all multicellular animals. They are the most abundant proteins in mammals, constituting 25% of their total protein. The central feature of all collagen molecules is their stiff, triple- stranded helical structure. Three collagen polypeptide chains, called alpha-chains, are wound around each other in a regular helix to generate a ropelike collagen molecule about 300 nm long and 1.5 nm in diameter. At most, eleven genetically distinct collagen types have been well defined.
- Types I, II, III, IV and V are the main types of collagen found in connective tissues, and of these, type I is much the most common, constituting about 75% of the collagen in the body.
- types I, II and III collagen molecules After being secreted into the extracellular space, types I, II and III collagen molecules assemble into ordered polymers called collagen fibrils, which are long (up to many microns) , thin (10 to 300 nm in diameter) , cablelike structures clearly visible in electron micrographs. Such fibrils are often grouped into larger bundles, which can be seen in the light microscope as collagen fibers several microns in diameter.
- SUBSTITUTE SHEET Type IV molecules (the main collagen in basal laminae) and type V and VI (found in small amounts near basal laminae and interstitially) do not form cross-banded fibrils.
- Tissue such as skin requires elasticity in addition to tensile strength in order to function.
- An extensive network of elastic fibers in the extracellular matrix of these tissues gives them the required ability to recoil after transient stretch.
- the main component of elastic fibers is elastin, a 70, 000-dalton glycoprotein, which, like collagen, is unusually rich in proline and glycine but, unlike collagen, contains little hydroxyproline and no hydroxylysine.
- Glycosaminoglycans formerly known as mucopolysaccharides, are long, unbranched polysaccharide chains composed of repeating disaccharide units. They are now called glycosaminoglycans because one of the two sugar residues in the repeating disaccharide is always an amino sugar (N-acetylglucosamine or-N-acetylgalactosamine) . Glycosaminoglycans are highly negatively charged due to the presence of sulfate or carboxvl groups or both on many of the sugar residues.
- glycosaminoglycans Seven groups of glycosaminoglycans have been distinguished by their sugar residues, the type of linkage between these residues, and the number and location of sulfate groups. They are hyaluronic acid (the only group in which none of the sugars is sulfated) , chondroitin 4-sulfate, chondroitin 6-sulfate, dermatan sulfate, heparan sulfate, heparin, and keratan sulfate.
- Hyaluronic acid also called hyaluronate or hyalurouan
- Hyaluronic acid exists as a single, very long carbohydrate chain of several thousand sugar residues in a regular, repeating sequence of disaccharide units.
- SUBSTITUTE SHEET acid is not typical of the glycosaminoglycans. • First, the others tend to contain a number of different disaccharide units arranged in more complex sequences. Second, the others have very much shorter chains, consisting of fewer than 300 sugar residues. Third, all of the other glycosaminoglycans are covalently linked to protein to form proteoglycan molecules.
- Proteoglycans are different from typical glycoproteins. Glycoproteins usually contain from 1% to 60% carbohydrate by weight in the form of numerous, relatively short (generally less than 15 sugar residues) , branched oligosaccharide chains of variable composition, which often terminate with sialic acid. In contrast, proteoglycans are much larger (up to millions of daltons) , and they usually contain 90% to 95% carbohydrate by weigh”.: in the form of many long, unbranched glycosaminoglycan chains, usually without sialic acid.
- Non-collagen glycoproteins that: are present in the extracellular matrix include fibronectin, a fiber- forming glycoprotein (about 5% carbohydrate by weight) composed of two disulfide-bonded subunits of 220,000 daltons each.
- Fibronectin exists as large aggregates in the extracellular space. While most of the protein is not. directly bound to cells, some of it is bound to the surfaces of fibroblasts and other cells when they are grown in culture. Purified fibronectin has been shown to promote the adhesion of a variety of cell types to other cells, as well as to collagen and other substrates.
- the matrix contains three major fiber-forming proteins - collagen, elastin, and fibronectin - which are interwoven in a hydrated gel formed by a network of glycosaminoglycan chains. All of the macromolecules are secreted locally bv cells in contact with the matrix.
- the collagens are ropelike, triple-stranded, helical molecules that aggregate in long cablelike fibrils or sheets in the extracellular space. These fibrils in turn can assemble in a variety of highly ordered arrays.
- Elastin molecules form an extensive cross-linked network of fibers and sheets that can stretch and recoil, imparting elasticity to the matrix.
- Fibronectin molecules form fibers that promote cell adhesion.
- the glycosaminoglycans are a heterogeneous group of long, negatively charged polysaccharide chains that (except for hyaluronic acid) are covalently linked to protein to form giant proteoglycan molecules.
- a cosmetic preparation containing collagen of the basement membrane is also disclosed in German Patent DE-PS 30 46 133.
- the use of the basement membrane collagen (collagen type IV) is therein claimed to have a higher effectiveness, since said basement membrane collagen is adopted better by the cells.
- the stated object of using basement membrane collagen was to promote regeneration and faster growth of new skin cells.
- the cosmetic preparation tries to counteract a feature of skin aging by supplying an individual substance.
- SUBSTITUTE SHEET U.S. Patent 4,451,397 discloses the use of collagen in connection with mucopolysaccharides for cosmetic purposes.
- the main subject matter of the invention disclosed in this patent is a method for producing a solution or a homogeneous gel composition _ consisting of the aforementioned substances, and the use of these substances in a cosmetic preparation to improve skin tone.
- Chemical Abstracts, Vol. 101, 1984, No. 78679 b discloses a cosmetic preparation containing fibronectin, which serves as a nutrient for the skin. 0
- Patent 4,327,078 to Charlet et al. discloses cosmetic agents containing, as an active ingredient, soluble elastin for treatment of aging skin.
- U.S. Patent 4,464,362 discloses cosmetic compositions containing inactive cultures of * bacteria of the genus 0 Bifidobacterium or bacteria related to this genus for promoting DNA repair in skin cells.
- the present invention provides a novel ophthalmic agent comprised of a sterilized extracellular connective tissue matrix wherein all of the extracted components are in the same structural form in which they existed _in vivo and are in the same physiological proportions to each other in which they existed in vivo. It is also an aspect of this invention that this ophthalmic agent be combined with a pharmaceutically acceptable carrier to form an ophthalmic composition.
- This invention also provides for the utilization of the ophthalmic agent or composition in a method for treatment of aged or damaged corneal tissue, so as to result in a repair of the cornea. It is a goal of this treatment that the cornea will improve in healing rate as a result of application of the ophthalmic agent or composition. The precise details of the invention will be further describee below.
- damaged corneal tissue is provided with the essential components as extracts of the extracellular connective tissue matrix in their native in vivo structural form as a novel ophthalmic agent. These components are provided in their naturally occurring physiological proportions as represented in their particular extracellular connective tissue matrix source.
- Thfe reference, Miller, E.J. et al., preparation and characterization of the different types of collagen, Methods in Enzymoloqy, 82 Part A: 33-64 (1982) 0 also discloses extraction methods useful in preparation cf the extract of this invention.
- Fetal or fetal associated membranes of mammals which are preferably used as starting material can be, for 5 example, placenta, blood vessels and umbilical cords as a sole source or in admixture with each other.
- the mammalian membrane source may be mammals such as cows (bovine) , sheep (ovine) , or pigs (porcine) .
- the tissue is rinsed with water to remove the blood.
- the tissue is then defatted, preferably with acetone, frozen preferably in liquid nitrogen and minced
- SUBSTITUTE SHEET U in a mill, e.g. in a blender.
- the disintegrated tissue obtained in this way is pre-treated with known protease inhibitors (as cited in Miller, supra) in appropriate buffer solutions of relatively high ionic strength.
- the purpose of said treatment is to minimize proteolysis by endogenous proteases, by inactivating the proteases.
- the disintegrated tissue is separated, preferably centrifuged, and the sediment is thoroughly washed with water, preferably at ambient temperature.
- tissue mass treated in this way is solubilized by adjusted and graduated steps of extraction to obtain native components in the same physiological proportions as in the original membrane source.
- the native, acid- soluble collagen molecules of types I and III are extracted preferably at about 4'C under acidic condition (preferably of less than pH5) and low ionic strength according to methods known in the art.
- acidic condition preferably of less than pH5
- low ionic strength preferably of less than pH5
- Acetic acid preferably of a concentration of about 0.1 to 0.5 M, is preferably used as extracting agent.
- the suspension containing the collagen is separated preferably by centrifugation and the sediment is washed in de-ionized water preferably about five times.
- salt solutions of high ionic strength such as 1 M NaCl.
- salt solutions of high ionic strength such as 1 M NaCl.
- other salt solutions such as
- 2 M MgCl 2 M to 4 M guanidine hydrochloride or 5 M urea, may also be used.
- the suspension obtained in this step is separated preferably by centrifugation.
- the supernatant, which is retained, contains the desired solubilized components in their native form.
- the sediment is again thoroughly washed in de-ionized water preferably about five times.
- collagen of types IV, V, VI and VII, and collagens of types I and III which are more cross-linked and which could not be extracted in the first extraction step by the method described herein are solubilized by a limited proteolysis, preferably using pepsin, preferably at temperatures from about 4 to about 18°C (Miller et al., Biochemistry 11, 4903, 1972).
- the extract is separated preferably by centrifugation.
- the proteolytic extraction step is repeated in order to obtain an extraction which results in a complete solubilization of the starting material.
- the mixture obtained in this way is the inventive ophthalmic agent of the extracellular connective tissue matrix extract in physiological proportions and in their native form. These solubilized components are present in macromolecular aggregates. Since this composition is for use in the eye, it is preferable that prior to application, it be sterilized by any number of methods known to those of skill in the art.
- the ophthalmic agent may be mixed with a pharmaceutically acceptable ophthalmic carrier to form a ophthalmic composition which may be directly or topically applied to the cornea.
- This ophthalmic composition or ophthalmic agent may be applied to the cornea in biologically or therapeutically effective amounts over a period of time which is sufficient to result in repair or remodeling of the cornea tissue. This repair or remodeling will typically be apparent from a decrease in the time needed for the healing process to repair the cornea tissue.
- the particular amount of ophthalmic agent or composition to be applied to the cornea and the duration or number of applications can be determined by an ophthalmologist on an individual basis by utilizing the agent or composition until a visible improvement of the corneal tissue results.
- Examples of typical and preferable treatments would be application two or three times a day with a ophthalmic composition containing about 10% of the ophthalmic agent.
- the percentage of ophthalmic agent present in the composition would vary, of course, depending upon the carrier and the severity of the corneal damage to be treated by the agent.
- the sterile opthalmic agent or composition may be utilized in methods of treating damage to other tissues of the human body.
- the Application of the above agent or composition to a torn or otherwise damaged cartilage (i.e. cartilage leisions or erosion of the articular cartilage) or joint via intra-articular injection would be helpful in the repair and healing process of the damage.
- an injection of this agent or composition may be useful in the treatment of arthritis.
- this agent or composition would be useful in treatment of other disease states, such as those involving the treatment of uterine conditions. Specifically, one possible application of this agent or composition would involve treating conditions of the .
- this agent or composition may be useful in the re-epithielization of the portio of the uterus.
- the method of application or delivery of this agent or composition to the uterus would be in a standard manner known to those of ordinary skill in the medical arts.
- ophthalmic or "ophthalmic composition” as used herein is intended to include all types of products which are applied in any manner directly to the person and is intended to include, in addition to the ophthalmic agent invention disclosed herein, conventional pharamceutically acceptable carriers such as water, saline and polyethelene glycol.
- compositions may take the form of fatty or emulsions of the water-in-oil or oil-in-water types, gels or jellies, colloidal or non colloidal aqueous or oily solutions.
- the amount of active ingredient contained in ophthalmic compositions according to the invention applied to the cornea may vary between wide limits, depending from the formulation and the frequency of use of said compositions.
- said compositions contain from 0.1%-99% by weight of the extracellular connective tissue matrix extract.
- the extracellular connective tissue matrix extract is in a sterile form.
- the ophthalmic compositions used in the method according to the invention may also contain conventional antibiotic, anti-inflammatories, ophthalmic lubricants such as carboxymethyl cellulase, or anesthetics. More specifically, it is foreseeable in the practice of this invention that the sterile extracellular matrix may be combined with the following antibiotics or antiviral compounds (typically in drop or ointment form with the preferred indicated typical dosages) :
- Neomycin 5-8 mg/ml
- anti-inflammatories may also be utilized with the sterile extracellular matrix composition of this invention in solution or ointment form:
- topical anesthetics may also be used in combination with the extracellular matrix composition:
- compositions may also be utilized in combination with the extracellular matrix composition:
- an ointment and related compositions containing the active composition may be formulated as follows:
- An aqueous solution containing the active composition (the extracellular connective tissue matrix extract prepared according to the present invention) may
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
An ophthalmic agent for physiological remodeling and repairing the epithelial-matrix junction of aging human cornea and/or human cornea damaged, for example, by ultraviolet radiation. The agent contains the essential components of the extracellular connective tissue matrix in native form and in physiological proportions. The components are obtained from mammals.
Description
OPTHALMIC AGENT AND RELATED COMPOSITIONS AND METHOD FOR TREATMENT OF THE CORNEA
1. INTRODUCTION
This invention relates to ophthalmic agents and compositions for the repair and remodeling of damaged corneal tissue. This invention also relates to a method for treating damaged corneal tissue with these agents and compositions.
Damage to the cornea can be attributed to a variety of factors. Some of these factors are ultraviolet radiation, aging, thermal and chemical burns (acid or alkali) and physical trauma. It is important from a therapeutic point of view to conserve an intact epithelial-matrix junction membrane and to assist in the rapid repair of damaged corneal tissue. Since a damaged cornea results in limited visual functionality.
The underlying problem addressed by the present invention has been the inability, to date, to provide a composition or treatment which would enable the repair damaged corneal tissue. This invention, therefore, relates to ophthalmic agents, compositions and methods for their use which, utilizing appropriate therapy, are effective in repairing and remodeling damaged corneal tissue. More specifically, the ophthalmic agents utilized in this invention provide essential components of the extracellular connective tissue matrix in their natural or native, unaltered structural form, which provide a physiological matrix required to repair damaged corneal tissue. The result of treatment with these ophthalmic agents is a cornea wherein the normal physiological visual functioning has been restored.
SUBSTITUTE SHEET
ϋ
2 . BACKGROUND OF THE INVENTION
2.1 EYE STRUCTURE
The eye, apart from its physical shape, has many of the structural features of the camera. The eyelids compromise the shutter. The iris is a diaphragm which contacts and dilates automatically in relation to the amount of light available. The eye has a lens composed of altered transparent epithelial cells but which is more elastic than the glass lens of a camera. The lens of the eye, as opposed to a camera, is suspended in such a way that muscle action can alter its shape and so change its focal length. As a consequence, the eye need not be shortened or elongated when objects at different distances are successively brought into focus as is necessary in a camera with a rigid lens. The a camera has its counterpart in the eye in strong connective tissue membrane, the sclera. The counterpart in the eye of the light-sensitive film used in a camera is a membrane of living cells of nervous origin, the retina, which lines not only the back but the sides of the eye as well. Then, finally, just as black is used to blacken all the interior surfaces of a camera that might leak or reflect light, black pigment is distributed generously between the retina and the sclera and in other sites where it would be useful.
However, unlike many modern cameras, the lens of the eye is not placed at its very front. The eye has its external aperture covered with a "glass window to keep out the dust", and its lens inside, a short distance behind the glass window. The transparent window in the central part of the front of the eye is of a curved form and is called the cornea. This is composed chiefly of a tough but:
SUBSTITUTE SHEET
transparent type of dense connective tissue that is continuous with the opaque connective tissue of the scler that surrounds and supports the remainder of the eye.
The cornea plays a larger role than the lens in - focusing the image upon the retina because light retina because light rays are bent more in passing from air into and out of the lens.
The surface of the cornea is curved so that light rays coming from a single point source hit the cornea at different angles and are bent different amounts. But all in such a way that they are directed to a point after emerging from the lens.
The shape of the cornea and lens and the length of the eyeball determine the point where light rays reconverge. Although the cornea performs the greater part quantitatively of focusing the visual image on the retina, all adjustments of distance are made by changing the shap of the lens. Such changes are called accommodation. The shape of the lens is controlled by a muscle which flattens the lens when distant objects are to be focused upon the retina and allows it to assume a more spherical shape to provide additional bending of the light rays when rear objects are viewed.
2.1.1 CORNEA STRUCTURE
The cornea is the anterior part of the supporting layer of the eye. It is a transparent, nonvascular membrane. It has a shorter radius of curvature than the remainder of the wall of the eye. Since it is exposed, it is subject to cuts, abrasions and other kinds of trauma. It is important in treating
SUBSTITUTE SHEET
l
\ injuries of the cornea to know its thickness. It is about 0.5 mm. thick at its central part and somewhat thicker at its periphery.
The cornea consists chiefly of a special kind of dense connective tissue, containing both cells and intercellular substance, called the substant a propria.
This bordered anteriorly and posteriorly by a membrane of homogeneous intercellular substance. Anteriorly, the cornea is covered with stratified squamous nonkeratinizing epithelium and posteriorly it is lined by a single layer of endothelial cells.
The epithelium covering the cornea is several layers in thickness and is replete with nerve endings tha~ are chiefly of the pain type. Their stimulation results reflexly in the blinking of the eyelids and in the flow of tears (mucus from the conjunctival glands also helps keep the corneal surface wet) ; if the nerve pathways concerned in the reflexes described above are destroyed, the corneal surface, on not being frequently wiped by the wet lids, becomes dry and then ulcerated. There are no papillae projecting into the epithelium of the cornea. Furthermore, since the connective tissue beneath it has no capillaries, the epithelium of the cornea is a comparatively long way from source of nutrition. The diffusion phenomenon on which its cells depend must be very efficient, for corneal epithelium, on being injured, regenerates rapidly. Carbon dioxide is eliminated through the corneal epithelium.
The membrane of intercelluar substance on which the basal cells of the corneal epithelium rests is called Bowman's membrane. This consists of a transσarent
SUBSTITUTE SHEET
homogeneous material. It is generally regarded as a condensation of the intercellular substance of the substantia propria. It contains some collagen and is regarded as an important protective layer, being resistant to trauma and bacterial invasion. Once destroyed, it does not regenerate. Bowman's membrane does not extend from the cornea into the sclera. The site at which cornea undergoes a transition into sclera and consequently, where Bowman's membrane ends is called the limbus.
The substantia propria comprises about 90 percent of the thickness of the cornea. It contains flattened connective tissue cells that are disposed between parallel bundles of collagenic fibers called lamellae. While most of the fibers in the lamella are disposed parallel with surface, those of one lamella run at an angle to those of the next. The fibers of some lamellae join with those of adjacent lamellae to bind the substantia propria together.
In the substantia propria the collagen fibrils and fibers are embedded in sulfated mucopolysaccharide containing proteoglycans and glycoproteins. It is assumed that the binding together of collagen fibrils in the substantia propria by the substance as well as their regular arrangement is responsible for the unique transparency of this membrane.
Deep to the substantia propria is Descement's membrane. This is composed of a special kind of material that appears to be homogeneous and seems to be chiefly an special form of collagen. Applied to the inner side of Descement's membrane is a single layer of endothelial cells; this laver is called Descement's endotheliu .
SUBSTITUTE SHEET
2.1.2 DAMAGE TO CORNEA
Trauma to the eye or adjacent structures requires meticulous examination to determine the extent of injury. The patient's vision, the range of extraocular motion, the location of lid and conjunctival lacerations and of foreign bodies, and the clarity of the ocular media should be carefully determined.
Conjunctival and corneal injuries by foreign bodies are the most frequent eye injuries. Seemingly minor trauma can be serious if ocular penetration is unrecognized or if secondary infection follows a corneal abrasion.
The treatment typically is adequate light, good anesthesia, and proper instruments are essential to ensure minimal trauma when removing embedded foreign bodies. Fluorescein staining renders foreign bodies and abrasions more apparent. An anesthetic is instilled onto the conjunctiva. Both lids are everted and the entire conjunctiva and cornea inspected with a binocular lens (loupe) . Conjunctival foreign bodies are lifted out with a moist sterile cotton applicator. A corneal foreign body that cannot be dislodged by irrigation may be lifted out carefully on the point of a sterile spud or hypodermic needle, under loupe magnification.
If the foreign body was tiny, only an antibiotic ointment (e.g., erythromycin 0.5% or bacitracin 500 u./gm) is typically instilled. If larger, however, treatment is that for any corneal abrasion is usually dilating the pupil with a short-acting cycloplegic, instilling an antibiotic, usually erythromycin or bacitracin; and applying a patch firmly enough to keep the eye closed
SUBSTITUTE SHEET
overnight. The corneal epithelium regenerates rapidly; under a patch, large areas will heal within 1 to 3 days. Follow-up examination by an ophthalmologist 1 or 2 days after injury is wise, especially if the foreign body was removed with a needle or spud.
5 .
Chemical burns of the cornea and conjunctiva can be serious and are usually treated immediately by copious irrigation with water or other bland fluids. The eye may be anesthetized, if it is available, but irrigation should never be delayed and should be carried out for 5 to 30
10 min. depending on the estimate of chemical contact.
Irrigation until the pH is neutral (as measured with paper indicators) is a reasonable end-point. Pain results from loss of corneal epithelium and chemical iritis, which is usually treated by instilling a long-acting cycloplegic,
15 applying an antibiotic ointment, and patching. Initially, pain may require codeine 30 to 60 mg orally or meperidine
50 mg IM q 4 h. Severe burns require -specialized treatment by an Ophthalmologist to save vision and prevent major complications such as iridocyclitis, perforation of
20 the globe, and lid deformities.
Various other forms of damage to the cornea may also occur in other fashions.
" In superficial punctuate keratitis scattered, fine, punctuate loss of epithelium from the corneal surface may occur in one or both eyes. It is often associated with trachoma, staphylococcal blepharitis, conjunctivitis, or a respiratory tract infection. It may
30 be due to a viral infection or may be. a reaction to local medication and is commonly the cause of intense pain after exposure to ultraviolet rays (e.g., from welding arcs, sun
5
SUBSTITUTE SHEET
lamps) . Symptoms include photophobia, pain, lacrimation, conjunctival injection, and diminution of vision. An enlarged preauricular node may be present in viral cases. Lesions due to ultraviolet ray exposure do not appear until several hours after the exposure; they last 24 to 43 h. while those secondary to viral or bacterial agents may last for months. Healing is spontaneous and residual vision impairment is rare, regardless of etiology. Typically topical antimicrobial therapy is given promptly, particularly if a causative organism can be cultured and identified. A systemic analgesic may be needed for control of pain.
In corneal. ulcers a local necrosis of corneal tissue is due to invasion by microorganisms. A pneumococcal, streptococcal, or staphylococcal infection following trauma or complicating a corneal foreign body is the usual primary cause. Corneal ulcers also occur as complications of herpes simplex keratitis, chronic blepharitis, conjunctivitis (especially bacterial) , trachoma, dacryocystitis, gonorrhea, and acute infectious diseases. Pain, photophobia, blepharospasm, and lacrimation are usually present, but may be minimal.
Ulceration without extensive infiltration may occur in herpes simplex. Fungal ulcerations are densely infiltrated and show occasions discrete islands of infiltrate (satellite lesions) at the periphery. The deeper the ulcer, the more severe the symptoms and complications. Ulcers deep enough to involve Bowman's membrane and the substance of the cornea heal with fibrous tissue replacement, causing opaque scarring of the cornea and decreased vision. Phlyctenular
Keratoconjunctivitis is a form of conjunctivitis, usually- occurring in children, characterized by discrete nodular
SUBSTITUTE SHEET
_ areas of inflammation (phlyctenules) and resulting from the atopic reaction of hypersensitive conjunctiva or cornea to an unknown allergen. Proteins of staphylococcal, tuberculous, or other bacterial origin have been implicated. The disease is rare in the USA.
Interstitial keratitis is a form of a chronic nonulcerative infiltration of the deep layers of the cornea, with uveal inflammation. It is rare in the USA. Most cases occur in children as late complication of congenital syphilis. Ultimately, both eyes may be involved. Rarely, acquired syphilis or tuberculosis may cause a unilateral form in adults. Photophobia, pain, lacrimation, and gradual loss of vision are common. The lesion begins in the deep corneal layers; soon the entire cornea develops a ground-glass appearance, obscuring the iris. New blood vessels grow in from the li bus and produce orange-red areas ("salmon patches"). Iritis, iridocyclitis, and choroiditis are common.
Kerato alacia is. a condition associated with vitamin A deficiency and protein-calorie malnutrition, characterized by a hazy, dry cornea that becomes denuded. Corneal ulceration with secondary infection is common. The lacrimal glands and conjunctiva are also affected. Lack of tears cause extreme dryness of the eyes, and foamy Bitot's spots 'appear on the bulbar conjunctiva. Nigh- blindness may be associated. Antibiotic ointments or sulfonamides (e.g., sulfacetamide ophthalmic solution 30% or ointment 10%) are required if secondary infection exists.
Keratoconus is a slowly progressive ectasia of the cornea , usually bilateral , beginning between ages 10 and 20 . The cone shaoe that the cornea assumes causes
SUBSTITUTE SHEET
Ao major changes in the refractive power of the eye, necessitating frequent change of spectacles. Contact lenses provide better visual correction, and should always be tried when eyeglasses are not satisfactory. Surgery may be necessary if the cornea becomes thin or if scarring follows rents in the posterior corneal surface.
Bullous keratopathy is a condition caused by excessive fluid accumulation in the cornea, most frequently the result of aging and failure of the posterior corneal endothelium. It is seen occasionally after intraocular operations (e.g., for cataract), where the mechanical stresses further interfere with the process of corneal detumescence.
2.2 EXTRACELLULAR MATRIX
Most cells in multicellular organisms are in contact with an intricate meshwork of interacting, extracellular macromolecules that constitute the extracellular matrix. These versatile protein and polysaccharide molecules are secreted locally and assemble into an organized meshwork in the extracellular space of most tissues. In addition to serving as a type of universal biological glue, they also form highly specialized structures such as cartilage, tendons, basal laminae, and (with the secondary deposition of a form of calcium phosphate crystals) bone and teeth.
Until recently, the vertebrate extracellular matrix was thought to serve mainly as a relatively inert scaffolding that stabilized the physical structure of tissues. But now it is clear that the matrix plays a far
SUBSTITUTE SHEET
more active and complex role in regulating the behavior of the cells that contact it - influencing their development, migration, proliferation, shape, and metabolic functions.
The macromolecules that constitute the extracellular matrix are secreted by local cells, especially fibroblasts, which are widely distributed in the matrix. Two of the main classes of extracellular macromolecules that make up the matrix are (1) the collagens and (2) the polysaccharide glycosaminoglycans, which are usually covalently linked to protein to form proteoglycans. The glyσosaminoglycan and proteoglycan molecules form a highly hydrated, gel-like "ground substance" in which collagen fibers are embedded. While the long collagen fibers strengthen and help to organize the matrix, the aqueous phase of the polysaccharide gel permits the diffusion of nutrients, metabolites, and hormones between the blood and the tissue cells. In many cases, fibers 'of the rubberlike protein elastin are also present and impart resilience to the matrix. In addition, two high molecular weight glycoproteins are among the major components of extracellular matrices: fibronectin, which is widely distributed in connective tissues, and laminin, which has so far been found only in basal laminae.
The term connective tissue is often used to describe the extracellular matrix plus the cells found in it, such as fibroblasts, macrophages, and mast cells. The amount of connective tissue in organs varies greatly: the cornea, skin and bone are composed mainly of connective tissue, whereas the brain and spinal cord contain very little. Moreover, the relative amounts of the different types of matrix macromolecules and the way that they are
SUBSTITUTE SHEET
organized within the extracellular matrix vary enormously, giving rise to a diversity of forms, each highly adapted to the functional requirements of the particular tissue. Thus, the matrix can become calcified to form the rock- hard structures of bone or teeth, it may take on the ropelike organization of the collagen fibers in tendons, which gives them their enormous tensile strength, or it can form a clear window-like structure in the cornea.
The collagens are a family of highly characteristic fibrous proteins found in all multicellular animals. They are the most abundant proteins in mammals, constituting 25% of their total protein. The central feature of all collagen molecules is their stiff, triple- stranded helical structure. Three collagen polypeptide chains, called alpha-chains, are wound around each other in a regular helix to generate a ropelike collagen molecule about 300 nm long and 1.5 nm in diameter. At most, eleven genetically distinct collagen types have been well defined.
The major types are referred to as types I, II, III, IV and V. Types I, II and III are the main types of collagen found in connective tissues, and of these, type I is much the most common, constituting about 75% of the collagen in the body. After being secreted into the extracellular space, types I, II and III collagen molecules assemble into ordered polymers called collagen fibrils, which are long (up to many microns) , thin (10 to 300 nm in diameter) , cablelike structures clearly visible in electron micrographs. Such fibrils are often grouped into larger bundles, which can be seen in the light microscope as collagen fibers several microns in diameter.
SUBSTITUTE SHEET
Type IV molecules (the main collagen in basal laminae) and type V and VI (found in small amounts near basal laminae and interstitially) do not form cross-banded fibrils.
Tissue such as skin requires elasticity in addition to tensile strength in order to function. An extensive network of elastic fibers in the extracellular matrix of these tissues gives them the required ability to recoil after transient stretch. The main component of elastic fibers is elastin, a 70, 000-dalton glycoprotein, which, like collagen, is unusually rich in proline and glycine but, unlike collagen, contains little hydroxyproline and no hydroxylysine.
Glycosaminoglycans, formerly known as mucopolysaccharides, are long, unbranched polysaccharide chains composed of repeating disaccharide units. They are now called glycosaminoglycans because one of the two sugar residues in the repeating disaccharide is always an amino sugar (N-acetylglucosamine or-N-acetylgalactosamine) . Glycosaminoglycans are highly negatively charged due to the presence of sulfate or carboxvl groups or both on many of the sugar residues. Seven groups of glycosaminoglycans have been distinguished by their sugar residues, the type of linkage between these residues, and the number and location of sulfate groups. They are hyaluronic acid (the only group in which none of the sugars is sulfated) , chondroitin 4-sulfate, chondroitin 6-sulfate, dermatan sulfate, heparan sulfate, heparin, and keratan sulfate.
Hyaluronic acid (also called hyaluronate or hyalurouan) exists as a single, very long carbohydrate chain of several thousand sugar residues in a regular, repeating sequence of disaccharide units. Hyaluronic
SUBSTITUTE SHEET
acid, however, is not typical of the glycosaminoglycans. • First, the others tend to contain a number of different disaccharide units arranged in more complex sequences. Second, the others have very much shorter chains, consisting of fewer than 300 sugar residues. Third, all of the other glycosaminoglycans are covalently linked to protein to form proteoglycan molecules.
Proteoglycans are different from typical glycoproteins. Glycoproteins usually contain from 1% to 60% carbohydrate by weight in the form of numerous, relatively short (generally less than 15 sugar residues) , branched oligosaccharide chains of variable composition, which often terminate with sialic acid. In contrast, proteoglycans are much larger (up to millions of daltons) , and they usually contain 90% to 95% carbohydrate by weigh".: in the form of many long, unbranched glycosaminoglycan chains, usually without sialic acid.
Non-collagen glycoproteins that: are present in the extracellular matrix include fibronectin, a fiber- forming glycoprotein (about 5% carbohydrate by weight) composed of two disulfide-bonded subunits of 220,000 daltons each. Fibronectin exists as large aggregates in the extracellular space. While most of the protein is not. directly bound to cells, some of it is bound to the surfaces of fibroblasts and other cells when they are grown in culture. Purified fibronectin has been shown to promote the adhesion of a variety of cell types to other cells, as well as to collagen and other substrates.
In sum, all cells in tissues are in contact with, an intricate extracellular matrix. This matrix not only- holds the cells together in tissues, and tissues together
SUBSTITUTE SHEET
in organs, but it also influences the development, polarity, and behavior of the cells it contacts. The matrix contains three major fiber-forming proteins - collagen, elastin, and fibronectin - which are interwoven in a hydrated gel formed by a network of glycosaminoglycan chains. All of the macromolecules are secreted locally bv cells in contact with the matrix.
The collagens are ropelike, triple-stranded, helical molecules that aggregate in long cablelike fibrils or sheets in the extracellular space. These fibrils in turn can assemble in a variety of highly ordered arrays. Elastin molecules form an extensive cross-linked network of fibers and sheets that can stretch and recoil, imparting elasticity to the matrix. Fibronectin molecules form fibers that promote cell adhesion. The glycosaminoglycans are a heterogeneous group of long, negatively charged polysaccharide chains that (except for hyaluronic acid) are covalently linked to protein to form giant proteoglycan molecules. All of these matrix proteins and polysaccharides are thought to interact and to assemble in a large variety of different three- dimensional structures, ordered in part by the cells secreting the matrix. Since the orientation of the matrix will in turn influence the orientation of the cells it contains, order is likely to be propagated from cell to cell through the matrix.
Research in the fields of cell biology and embryology has also shown that an extracellular connective tissue matrix consisting of genetically distinct collagen types, proteoglycans and structural glycoproteins has a significant influence on cell proliferation, itogenesis and morphogenesis (Hay, Mod. Cell. Biol. , 2: 509, 1983;
SUBSTITUTE SHEET
Bernfield et al. in: The Role of Extracellular Matrix in Development, A.R. Liss, New York, 1984) . It has been postulated that there exists a "dynamic reciprocity" between the extracellular matrix on the one hand, and the cytoskeleton and the nuclear matrix on the other hand. The extracellular matrix is thought to exert physical and chemical influences on the geometry and the biochemistry of the cell via transmembrane receptors so as to alter the pattern of gene expression by changing the association of the cytoskeleton with the mRNA, and the interaction of the chromatin with the nuclear matrix. Bissell, et al., J. Theor. Biol., 99: 31-63 (1982) .
The following references provide additional information concerning the extracellular matrix and its interactions with other tissue or cellular components. See, Hay, Cell and Extracellular Matrix, Modern Cell Biology, 2_: 509-548 (1983) and Kleinman, et al., Role of Collagenous Matrices in the Adhesion and Growth of Cells, Cell Biol. , 88 (3): 473-486 (1981).
These factors, when combined with the knowledge that these matrix macromolecules are further known to individually to affect the behavior of cells in culture, has lead the art to attempt to explore the contribution o the extracellular matrix in the development of eye (E.D. Hay, J. of Cellular Biochemistry, 27:143-156 (1985); the maintenance of its active structure (K.K. Svboda et al., J. Cell. Biol. 103:250(a) 1986) . Nakayasu, Opthalmic Res., 18:1-10 (1986); and in wound repair (S.R. Gordon, J. Cell. Bio., 103:250(a) 1986; Zieske, J. of Cell. Bio., 103:251(a) (1986)) A.K. Simonsen et al. , Exp. Eye Res., 3_5:287-292 (1982) ) .
SUBSTITUTE SHEET
2.3 EXTRACELLULAR MEMBRANE TREATMENT
To date the only application of components of the extracellular matrix has been in cosmetic skin preparations wherein individual active substances or combinations of isolated individual components of the b _ extracellular matrix are often used in the hope of preventing skin aging by substitution of deficient or damaged skin components.
For instance, skin preparations are disclosed in the German Patent DE-PS 20 64 604. This reference speaks of increasing the soluble, i.e. not cross-linked portion of the collagen in the skin, by using native soluble collagen (tropocollagen) to improve the age-dependent ratio of soluble to insoluble collagen in favor of the soluble fraction, and to slow down the loss of elasticity of the skin.
A cosmetic preparation containing collagen of the basement membrane is also disclosed in German Patent DE-PS 30 46 133. In contrast to the use of the interstitial collagen types I, II and III which are structurally similar to each other, the use of the basement membrane collagen (collagen type IV) is therein claimed to have a higher effectiveness, since said basement membrane collagen is adopted better by the cells. The stated object of using basement membrane collagen was to promote regeneration and faster growth of new skin cells. Thus the cosmetic preparation tries to counteract a feature of skin aging by supplying an individual substance.
SUBSTITUTE SHEET
U.S. Patent 4,451,397 discloses the use of collagen in connection with mucopolysaccharides for cosmetic purposes. The main subject matter of the invention disclosed in this patent is a method for producing a solution or a homogeneous gel composition _ consisting of the aforementioned substances, and the use of these substances in a cosmetic preparation to improve skin tone. Chemical Abstracts, Vol. 101, 1984, No. 78679 b discloses a cosmetic preparation containing fibronectin, which serves as a nutrient for the skin. 0
Other references additionally disclose the use of connective tissue components for skin treatment. U.S. Patent 3,991,184 to Kludas discloses the use of untreated, soluble collagen having an unchanged substantially non- cross-linked structure for use in treating the skin. U.S.
15 Patent 4,327,078 to Charlet et al. discloses cosmetic agents containing, as an active ingredient, soluble elastin for treatment of aging skin. In addition, U.S. Patent 4,464,362 discloses cosmetic compositions containing inactive cultures of* bacteria of the genus 0 Bifidobacterium or bacteria related to this genus for promoting DNA repair in skin cells.
The hitherto known cosmetic agents and the active substances and combinations of different individual 5 substances which have been used, however, have so far not considered the latest findings of research in connective tissue and cell biology in application to corneal injury.
Therefore, it is an object of the present
30 invention to assist in the repair of corneal tissue visual functioning via a reconstituted, repaired, and remodeled corneal tissue.
~-~~
SUBSTITUTESHEET
3. SUMMARY OF THE INVENTION
The present invention provides a novel ophthalmic agent comprised of a sterilized extracellular connective tissue matrix wherein all of the extracted components are in the same structural form in which they existed _in vivo and are in the same physiological proportions to each other in which they existed in vivo. It is also an aspect of this invention that this ophthalmic agent be combined with a pharmaceutically acceptable carrier to form an ophthalmic composition. This invention also provides for the utilization of the ophthalmic agent or composition in a method for treatment of aged or damaged corneal tissue, so as to result in a repair of the cornea. It is a goal of this treatment that the cornea will improve in healing rate as a result of application of the ophthalmic agent or composition. The precise details of the invention will be further describee below.
4. DESCRIPTION OF THE INVENTION
4.1 SOURCE, COMPOSITION AND EXTRACT PREPARATION
According to the present invention, damaged corneal tissue is provided with the essential components as extracts of the extracellular connective tissue matrix in their native in vivo structural form as a novel ophthalmic agent. These components are provided in their naturally occurring physiological proportions as represented in their particular extracellular connective tissue matrix source.
SUBSTITUTE SHEET
Surprisingly, it has been discovered that topical application of the essential components of an extract of the extracellular connective tissue matrix in physiological proportions leads to a repair of the corneal tissue damaged by aging or environmental factors such as 5- ultraviolet light, heat or chemical (acid or aldkali) burns or physical trauma. Normal corneal structure is restored with the application of the ophthalmic agent.
The structure and composition of the essential components of the extracellular connective tissue matrix
10 in physiological proportions and in their native structural form in vivo according to the present invention can be illustrated by one process set forth below for their preparation. This procedure is merely an exemplary way to extract the essential components of the
T5 extracellular connective tissue matrix in their native structural forms and in the same proportion as their proportions _in vivo. Thfe reference, Miller, E.J. et al., preparation and characterization of the different types of collagen, Methods in Enzymoloqy, 82 Part A: 33-64 (1982) 0 also discloses extraction methods useful in preparation cf the extract of this invention.
Fetal or fetal associated membranes of mammals which are preferably used as starting material can be, for 5 example, placenta, blood vessels and umbilical cords as a sole source or in admixture with each other. The mammalian membrane source may be mammals such as cows (bovine) , sheep (ovine) , or pigs (porcine) .
30 First, the tissue is rinsed with water to remove the blood. The tissue is then defatted, preferably with acetone, frozen preferably in liquid nitrogen and minced
SUBSTITUTE SHEET
U in a mill, e.g. in a blender. The disintegrated tissue obtained in this way is pre-treated with known protease inhibitors (as cited in Miller, supra) in appropriate buffer solutions of relatively high ionic strength. The purpose of said treatment is to minimize proteolysis by endogenous proteases, by inactivating the proteases.
After an incubation, preferably for about one hour, the disintegrated tissue is separated, preferably centrifuged, and the sediment is thoroughly washed with water, preferably at ambient temperature.
The tissue mass treated in this way is solubilized by adjusted and graduated steps of extraction to obtain native components in the same physiological proportions as in the original membrane source.
In the first extraction step, the native, acid- soluble collagen molecules of types I and III are extracted preferably at about 4'C under acidic condition (preferably of less than pH5) and low ionic strength according to methods known in the art. (Piez et al. , Biochemistry 2_, 58 (1963); Orekhovitch et al. , Biockhimya 13, 55 (1948) ; Kulonen et al., Proc. Soc. Ex . Biol. Med. 84, 424 (1954) ; Gallop, Arch. Bioch. Bioph. 5_4, 486 (1966) ) . Acetic acid, preferably of a concentration of about 0.1 to 0.5 M, is preferably used as extracting agent. However, formic acid of the same concentration, or acidic phosphate or citrate buffer, preferably at a concentration of 0.15 to 1.0 M, may also be used.
The suspension containing the collagen is separated preferably by centrifugation and the sediment is washed in de-ionized water preferably about five times.
SUBSTITUTE SHEET
The washed sedi amtent is then subsequently extracted to obtain proteoglycans and glycoproteins, such as fibronectin and laminin, and other known extracellular matrix components according to methods known in the art
(cf. Sajedera et al., J. Biol. Che . 244, 77 (1969)) preferably using salt solutions of high ionic strength, such as 1 M NaCl. However, other salt solutions, such as
2 M MgCl , 2 M to 4 M guanidine hydrochloride or 5 M urea, may also be used.
The suspension obtained in this step is separated preferably by centrifugation. The supernatant, which is retained, contains the desired solubilized components in their native form. The sediment is again thoroughly washed in de-ionized water preferably about five times.
In a third extraction step, collagen of types IV, V, VI and VII, and collagens of types I and III which are more cross-linked and which could not be extracted in the first extraction step by the method described herein, are solubilized by a limited proteolysis, preferably using pepsin, preferably at temperatures from about 4 to about 18°C (Miller et al., Biochemistry 11, 4903, 1972). The extract is separated preferably by centrifugation.
Preferably the proteolytic extraction step is repeated in order to obtain an extraction which results in a complete solubilization of the starting material.
SUBSTITUTE SHEET
Each individual extract obtained by the three extraction steps described above is adjusted to a pH-value of preferably 4.5 to 5.0. The extracts are then mixed by constant stirring at a low temperature, preferably about 4"C, until a homogeneous phase is obtained.
The mixture obtained in this way is the inventive ophthalmic agent of the extracellular connective tissue matrix extract in physiological proportions and in their native form. These solubilized components are present in macromolecular aggregates. Since this composition is for use in the eye, it is preferable that prior to application, it be sterilized by any number of methods known to those of skill in the art.
4.2 TREATMENT OF DAMAGED CORNEAL AND OTHER TISSUE
The ophthalmic agent, as disclosed below, may be mixed with a pharmaceutically acceptable ophthalmic carrier to form a ophthalmic composition which may be directly or topically applied to the cornea. This ophthalmic composition or ophthalmic agent may be applied to the cornea in biologically or therapeutically effective amounts over a period of time which is sufficient to result in repair or remodeling of the cornea tissue. This repair or remodeling will typically be apparent from a decrease in the time needed for the healing process to repair the cornea tissue.
The particular amount of ophthalmic agent or composition to be applied to the cornea and the duration or number of applications can be determined by an ophthalmologist on an individual basis by utilizing the agent or composition until a visible improvement of the corneal tissue results. One skilled in the art of
SUBSTITUTE SHEET
ophthalmology and who is familiar with standard treatment of corneal injures means would also be in a position to easily evaluate a beneficial course of treatment.
Examples of typical and preferable treatments would be application two or three times a day with a ophthalmic composition containing about 10% of the ophthalmic agent.
The percentage of ophthalmic agent present in the composition would vary, of course, depending upon the carrier and the severity of the corneal damage to be treated by the agent.
It is also within the scope of this invention that the sterile opthalmic agent or composition may be utilized in methods of treating damage to other tissues of the human body. For instance, it is within the scope of this invention that the Application of the above agent or composition to a torn or otherwise damaged cartilage (i.e. cartilage leisions or erosion of the articular cartilage) or joint via intra-articular injection would be helpful in the repair and healing process of the damage. For instance, an injection of this agent or composition may be useful in the treatment of arthritis. It is also foreseeable that this agent or composition would be useful in treatment of other disease states, such as those involving the treatment of uterine conditions. Specifically, one possible application of this agent or composition would involve treating conditions of the . endometrium or portio of the uterus. For instance, application of this agent or composition may be useful in the re-epithielization of the portio of the uterus. The method of application or delivery of this agent or composition to the uterus would be in a standard manner known to those of ordinary skill in the medical arts.
SUBSTITUTE SHEET
IS
4.3 OPHTHALMIC FORMULATIONS
The term "ophthalmic" or "ophthalmic composition" as used herein is intended to include all types of products which are applied in any manner directly to the person and is intended to include, in addition to the ophthalmic agent invention disclosed herein, conventional pharamceutically acceptable carriers such as water, saline and polyethelene glycol.
Said compositions may take the form of fatty or emulsions of the water-in-oil or oil-in-water types, gels or jellies, colloidal or non colloidal aqueous or oily solutions.
The amount of active ingredient contained in ophthalmic compositions according to the invention applied to the cornea may vary between wide limits, depending from the formulation and the frequency of use of said compositions. Generally, said compositions contain from 0.1%-99% by weight of the extracellular connective tissue matrix extract. Preferably the extracellular connective tissue matrix extract is in a sterile form.
The ophthalmic compositions used in the method according to the invention may also contain conventional antibiotic, anti-inflammatories, ophthalmic lubricants such as carboxymethyl cellulase, or anesthetics. More specifically, it is foreseeable in the practice of this invention that the sterile extracellular matrix may be combined with the following antibiotics or antiviral compounds (typically in drop or ointment form with the preferred indicated typical dosages) :
Ampicillin
Bacitracin 20,000 units/ml
Carbenicillin 4.0 mg/ml
SUBSTITUTE SHEET
2 έ
Cefazolin 50 mg/ml
Cephalothin 50 mg/ml
Chloramphenicol 5 mg/ml
Clindamycin
Colistin 5-10 mg/ml
Erythromycin 50 mg/ml
Gentamicin 8-15 mg/ml
Lincomycin
Methicillin
Neomycin 5-8 mg/ml
Penicillin G 100,000 units/ml
Polymyxin B 16,250 units/ml
Streptomycin
Sulfacetamide 100-300 mg/ml
Tobramycin 3 mg/ml
Vancomycin 50 mg/ml
Idσxuridine (IDU)
Trifluridine
Vidarabine (Adenine
Arabinoside, ARA-A) Acyclovir (Acycloguanosine) Pyrimethamine Sulfadiazine
Corticosteroid preparation Clindamycin Amphotericin B 2.5-10 mg/ml of diluent (distilled water of 5% dextrose solution)
Nystatin Ointment 100,000 units/GM
Natamycin 5% Suspension Miconazole
The following anti-inflammatories may also be utilized with the sterile extracellular matrix composition of this invention in solution or ointment form:
Hydrocortisone
Rednisolone
Dexamethasone
The following topical anesthetics may also be used in combination with the extracellular matrix composition:
Cocaine Hydrochloride Proparacaine Hydrochloride Tetracaine Hydrochloride
SUBSTITUTE SHEET
The following major component of demulcent
(artificial tear) compositions may also be utilized in combination with the extracellular matrix composition:
Hydroxethylcellulose Hydroxproplycellulose Hydroxypropyl methylcellulose Methylcellulose
Polyvinyl alcohol
Polyvinyl alcohol and cellulose ester Polyvinyl alcohol and povidone Other Polymeric Systems
A few examples of ophthalmic compositions used in methods according to this invention are given hereafter. These examples are only illustrative and must not be considered as limiting the scope of the invention. In said examples, the percentages are by weight.
The following formulations are exemplary embodiments of the invention, but are not intended to limit the scope of this invention or restrict it to these particular formulations:
4.4 OINTMENT
An ointment and related compositions containing the active composition (extracellular connective tissue matrix extract prepared according to the present invention) may be formulated as follows:
a) Petrolatum, Liquid Lanolin, Mineral Oil 90? or Sterile ointment containing white 90' petrolatum and mineral oil or Sterile ointment with white petrolatum, 90° liquid lanolin, mineral oil, methylparaben and polyparaben or Sterile ointment containing white 90° petrolatum and light mineral oil
SUBSTITUTE SHEET
S
Sterile ointment with 42.5% mineral (Total ) 97 . 5 = oil, 55% white petrolatum, and lanolin and c) active composition according to the present invention (prepared as explained above) 10.0-
4.5 AQUEOUS SOLUTION
An aqueous solution containing the active composition (the extracellular connective tissue matrix extract prepared according to the present invention) may
10 be formulated as follows:
a) active composition according to the 10.0' present invention (as in example 1) and
15 b) Saline (NaCl) or a combination of an 90% aqueous solution of salts such as Benzalkonium Chloride, Potassium
'Chloride', Disodium Edetate, Boric and Acid, Sodium Carbonate
0
25
30
~~
SUBSTITUTE SHEET
Claims
1. An ophthalmic composition comprising a sterile extracellular connective tissue matrix extract and
_ a pharmaceutically acceptable carrier.
2. The composition of claim 1 wherein the sterile extracellular connective tissue matrix extract is derived from a mammal.
3. The ophthalmic composition of claim 1 wherein the sterile extracellular connective tissue matrix extract is derived from an animal selected from the group consisting of bovine, ovine and porcine.
4. The ophthalmic composition of claim 2 or 3 wherein the sterile extracellular connective tissue matrix extract is derived from the tissue selected from the group consisting of placenta tissue, fetal membranes, blood vessels and umbilical cords.
5. The ophthalmic composition of claim 1 wherein the components of the sterile extracellular connective tissue matrix extract are present in their native structural form.
6. The ophthalmic compositions of claim 1 wherein the sterile extracellular connective tissue matrix extract is comprised of collagens, proteoglycans, glycosaminoglycans and glycoproteins.
SUBSTITUTE SHEET
7. The ophthalmic composition of claim 6 wherein the collagens comprise collagen types I, III, IV, V, VI and VII.
8. The ophthalmic composition of claim 7 wherein the collagens are present in their _in vivo physiological proportions.
9. The ophthalmic composition of claim 6 wherein the proteoglycans and glycosaminoglycans are solubilized and intact.
10. The ophthalmic composition of claim 6 wherein the proteoglycans, glycosaminoglycans and glycoproteins are present in the extract in their in. vivc physiological proportions.
11. The ophthalmic composition of claim 1 wherein the carrier is a cream.
12. The ophthalmic composition of claim 1 wherein the pharmaceutically acceptable carrier is an aqueous based solution.
13. The ophthalmic composition of claim 1 wherein the pharmaceutically acceptable carrier is oil- based.
14. The ophthalmic composition of claim 1 further comprising at least one compound selected from the group consisting of an antibiotic, anti-viral, anti- inflammatory anesthetic and demulcent.
SUBSTITUTE SHEET 15. The ophthalmic composition of claim 1 wherein the sterile extracellular connective tissue matrix extract comprises at least about .1% of said ophthalmic composition.
_ 16. An ophthalmic agent comprising a sterile extracellular connective tissue matrix extract.
17. The ophthalmic agent of claim 16 wherein the extract comprises collagens, proteoglycans, glycosaminoglycans and glycoproteins.
18. The ophthalmic agent of claim 17 wherein the collagens, proteoglycans, glycosaminoglycans and glycoproteins are present in their _in vivo physiological proportions.
19. The ophthalmic agent of claim 17 wherein collagens, proteoglycans and glycosaminoglycans are present in their native structural form.
20. The ophthalmic agent of claim 16 wherein the sterile extracellular connective tissue matrix is derived from a mammal.
21. The ophthalmic agent of claim 16 wherein the sterile extracellular connective tissue matrix is derived from an animal selected from the group consisting of ovine, bovine and porcine.
22. The ophthalmic agent of claim 17 wherein the collagens comprise collagen types I, III, IV, V, VI and VII.
SUBSTITUTE SHEET
23. The agent of claim 20 wherein the extracellular connective tissue matrix extract is derived from the tissue selected from the group consisting of placenta tissue, fetal membranes, blood vessels and umbilical cords.
5
24. A method of treating a damaged cornea comprising. applying a therapeutically effective amount of a composition comprising a sterile extracellular connective tissue matrix extract and pharmaceutically acceptable carrier to the cornea.
10
25. The method of claim 24 wherein the sterile extracellular connective tissue matrix extract and pharmaceutically acceptable carrier is applied topically.
T5
26. The method of claim 24 wherein the sterile extracellular connective tissue matrix extract is derived from a mammal.
27. The method of claim 24 wherein the sterile
20 extracellular connective tissue matrix extract is derived from an animal selected from the group consisting of bovine, ovine and porcine.
28. The method of claim 26 wherein the sterile
25 extracellular connective tissue matrix extract is derived from the tissue selected from the group consisting of placenta tissue, fetal membranes, blood vessels and umbilical cords.
30
35
SUBSTITUTE SHEET 29. The method of claim 24 wherein the components of the sterile extracellular connective tissue matrix extract are present in their native structural form.
- 30. The method of claim 24 wherein the sterile b extracellular connective tissue matrix extract is comprised of collagens, proteoglycans, glycosaminoglycans and glycoproteins.
31. The method of claim 24 wherein the collagens comprise collagen types I, III, IV, V, VI and VII.
32. The method of claim 31 wherein the collagens are present in their in vivo physiological proportions.
33. The method of claim 31 wherein the proteoglycans and glycosaminoglycans are solubilized and intact.
34. The method of claim 31 wherein the proteoglycans, glycosaminoglycans and glycoproteins are present in the extract in their _in vivo physiological proportions.
35. The method of claim 24 wherein the sterile extracellular connective tissue matrix extract comprises at least about .1% of said mixture.
36. The method of claim 24 wherein the sterile extracellular connective tissue matrix extract is applied at least a but once a day to said damaged cornea.
SUBSTITUTE SHEET 37. The method of claim 24 wherein the mixture is applied to the cornea over a period of time sufficient to reduce the time required to complete the healing process of the damaged cornea.
c 38. The ophthalmic composition of claim 1 wherein the pharmaceutically acceptable carrier is an acrueous based solution.
39. A method of treating damaged cartilage tissue comprising applying a therapeutically affective
10 amount of a composition comprising a sterile extracellular connective tissue matrix extract and pharmaceutically acceptable carrier to the damaged cartilage tissue.
40. The method of claim 39 wherein the damage to
15 the cartilage is caused by arthritis.
41. The method of claim 39 wherein the composition is provided to the damaged cartilage by intra- articular injection.
20
42. The method of claim 39 wherein the sterile extracellular connective tissue matrix extract is derived from a mammal.
251
43. The method of claim 39 wherein the sterile extracellular connective tissue matrix extract is derived from an animal selected from the group consisting of bovine, ovine and porcine.
30
35
SUBSTITUTE SHEET
44. The method of claim 42 wherein the sterile extracellular connective tissue matrix extract is derived from the tissue selected from the group consisting of placenta tissue, fetal membranes, blood vessels and umbilical cords.
45. The method of claim 39 wherein the components of the sterile extracellular connective tissue matrix extract are present in their native structural form.
46. The method of claim 39 wherein the sterile extracellular connective tissue matrix extract is comprised of collagens, proteoglycans, glycosaminoglycans and glycoproteins.
47. The method of claim 39 wherein the collagens comprise collagen types I, III, IV, V, VI and VII.
48. The method of claim 39 wherein the collagens are present in their in vivo physiological proportions.
49. The method of claim 39 wherein the proteoglycans and glycosaminoglycans are solubilized and intact.
50. The method of claim 39 wherein the sterile extracellular connective tissue matrix extract comprises at least about .1% of said mixture.
51. The method of claim 39 wherein the sterile extracellular connective tissue matrix extract is provided at least about once a day to said damaged cartilage.
SUBSTITUTE SHEET
52. The method of claim 39 wherein the mixture is provided to the cartilage over a period of time sufficient to reduce the time required to complete the healing process of the damaged cartilage.
,
53. A method for treating damaσed uterine tissue b comprising applying a therapeutically affective amount of a composition comprising a sterile extracellular connective tissue matrix extract and pharmaceutically acceptable carrier to the uterine tissue.
54. The method of claim 53 wherein the sterile extracellular connective tissue matrix extract and pharmaceutically acceptable carrier is applied topically.
55. The method of claim 53 wherein the sterile 5 extracellular connective tissue matrix extract is derived from a mammal.
56. The method of claim 53 wherein the sterile extracellular connective tissue matrix extract is derived 0 from an animal selected from the group consisting of bovine, ovine and porcine.
57. The method of claim 55 wherein the sterile extracellular connective tissue matrix extract is derived 5 from the tissue selected from the group consisting of placenta tissue, fetal membranes, blood vessels and umbilical cords.
58. The method of claim 53 wherein the 0 components of the sterile extracellular connective tissue matrix extract are present in their native structural form.
5
SUBSTITUTE SHEET
59. The method of claim 53 wherein the sterile extracellular connective tissue matrix extract is comprised of collagens, proteoglycans, glycosaminoglycans and glycoproteins.
60. The method of claim 53 wherein the collagens comprise collagen types I, III, IV, V, VI and VII.
61. The method of claim 53 wherein the collagens are present in their _in vivo physiological proportions.
62. The method of claim 53 wherein the proteoglycans and glycosaminoglycans are solubilized and intact.
63. The method of claim 53 wherein the sterile extracellular connective tissue matrix extract comprises at least about .1% of said mixture.
64. The method of claim 53 wherein the sterile extracellular connective tissue matrix extract is applied at least a but once a day to said damaged uterus.
65. The method of claim 53 wherein the mixture is applied to the uterine tissue over a period of time sufficient to reduce the time required to complete the healing process of the damaged uterine tissue.
SUBSTITUTE SHEET
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7099187A | 1987-07-08 | 1987-07-08 | |
US070,991 | 1987-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989000043A1 true WO1989000043A1 (en) | 1989-01-12 |
Family
ID=22098603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1988/000606 WO1989000043A1 (en) | 1987-07-08 | 1988-07-07 | Ophthalmic agent and related compositions and method for treatment of the cornea |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1966988A (en) |
WO (1) | WO1989000043A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006064672A1 (en) * | 2004-11-25 | 2006-06-22 | Japan Bioproducts Ind. Co. Ltd. | Therapeutic agent for ophthalmic diseases |
US10555897B1 (en) | 2013-03-16 | 2020-02-11 | Brahm Holdings Llc | Cosmetic composition and methods of treatment |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1730M (en) * | 1962-01-17 | 1963-03-18 | Charles Riviere | New composition of eye drops. |
FR6652M (en) * | 1966-12-28 | 1969-01-27 | ||
GB1386864A (en) * | 1972-02-11 | 1975-03-12 | Avicon Inc | Micro-crystalline collage-containing pharmaceutical compositions useful for topical applications |
US4042457A (en) * | 1975-11-10 | 1977-08-16 | Rush-Presbyterian-St. Luke's Medical Center | Preparation of tissue invasion inhibitor and method of treatment utilizing the inhibitor |
EP0154447A2 (en) * | 1984-02-24 | 1985-09-11 | The Regents Of The University Of California | Compositions and method for improving wound healing |
-
1988
- 1988-07-07 AU AU19669/88A patent/AU1966988A/en not_active Abandoned
- 1988-07-07 WO PCT/EP1988/000606 patent/WO1989000043A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1730M (en) * | 1962-01-17 | 1963-03-18 | Charles Riviere | New composition of eye drops. |
FR6652M (en) * | 1966-12-28 | 1969-01-27 | ||
GB1386864A (en) * | 1972-02-11 | 1975-03-12 | Avicon Inc | Micro-crystalline collage-containing pharmaceutical compositions useful for topical applications |
US4042457A (en) * | 1975-11-10 | 1977-08-16 | Rush-Presbyterian-St. Luke's Medical Center | Preparation of tissue invasion inhibitor and method of treatment utilizing the inhibitor |
EP0154447A2 (en) * | 1984-02-24 | 1985-09-11 | The Regents Of The University Of California | Compositions and method for improving wound healing |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006064672A1 (en) * | 2004-11-25 | 2006-06-22 | Japan Bioproducts Ind. Co. Ltd. | Therapeutic agent for ophthalmic diseases |
US10555897B1 (en) | 2013-03-16 | 2020-02-11 | Brahm Holdings Llc | Cosmetic composition and methods of treatment |
US11382859B1 (en) | 2013-03-16 | 2022-07-12 | Brahm Holdings, Llc | Cosmetic composition and methods of treatment |
Also Published As
Publication number | Publication date |
---|---|
AU1966988A (en) | 1989-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5036056A (en) | Methods for treating damaged corneal, uterine, or cartilage tissue | |
US4946450A (en) | Glucan/collagen therapeutic eye shields | |
US4716224A (en) | Crosslinked hyaluronic acid and its use | |
CA1205031A (en) | Hyaluronic acid fractions having pharmaceutical activity, and processes for the preparation thereof | |
US4486416A (en) | Protection of human and animal cells subject to exposure to trauma | |
US5137875A (en) | Hyaluronic acid-containing aqueous solution or aqueous dispersion of collagen | |
US5925626A (en) | Hyaluronic acid fractions having pharmaceutical activity, and pharmaceutical compositions containing the same | |
US4883864A (en) | Modified collagen compound and method of preparation | |
US5631243A (en) | Collagen-based viscoelastic solution for visco-surgery | |
US5627162A (en) | Methods and means for control of proliferation of remnant cells following surgery | |
Posarelli et al. | Cross-linked hyaluronic acid as tear film substitute | |
JPH0121133B2 (en) | ||
JPH11500032A (en) | Biodegradable eye shield | |
US4913904A (en) | Ophthalmological collagen coverings | |
Sebag et al. | Vitreous—from biochemistry to clinical relevance | |
EP4393521A1 (en) | Bionic cornea and preparation method therefor | |
RU2165749C1 (en) | Method for repairing corneal endothelium | |
MIYAUCHI et al. | The effect of sodium hyaluronate on the migration of rabbit corneal epithelium. I. An in vitro study | |
Aquavella et al. | Therapeutic applications of a collagen bandage lens: A preliminary report | |
JPH0723317B2 (en) | Corneal epithelial disorder treatment | |
Dische | Biochemistry of connective tissue of the vertebrate eye | |
WO1989000043A1 (en) | Ophthalmic agent and related compositions and method for treatment of the cornea | |
Forrest et al. | Comparative studies on the insoluble collagens of guinea-pig dermis and dermal scar tissue | |
CN110314252A (en) | Collagen Implant is preparing the purposes in operation for glaucoma auxiliary reconstruction | |
Arzeno et al. | Effect of sodium hyaluronate on corneal wound healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG BR DK FI HU JP KR MC NO RO SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |